Prior to joining Anaphore, Dr. Bowdish simultaneously served as President of Alexion Antibody Technologies and Senior Vice President of Alexion Pharmaceuticals [NASDAQ: ALXN]. Alexion Antibody Technologies, a wholly-owned subsidiary of Alexion Pharmaceuticals, was formed in September 2000 with the acquisition of Prolifaron. Dr. Bowdish was the founder, Chief Executive Officer and Chief Scientific Officer of Prolifaron, a privately held antibody discovery company that grew through partnerships with companies including Centocor and GSK, and emerged as an innovative leader in antibody therapeutics with a focus on developing new treatments for cancer, autoimmune disorders, and infectious diseases. Dr. Bowdish led the company from inception, to development of a portfolio of preclinical and clinical drug candidates, and ultimately through its acquisition by Alexion. She received her formal education in molecular genetics at Columbia University College of Physicians and Surgeons (Ph.D.) and in biology at the College of William and Mary (B.S.). Dr. Bowdish has published numerous peer-reviewed articles and has an extensive intellectual property portfolio, primarily focused in the area of molecular immunology.